Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10914687 | Molecular Oncology | 2014 | 10 Pages |
Abstract
In the first series, analyzed by MSP, CRC stage II patients (n = 233) with RET methylated tumors had a significantly worse overall survival as compared to those with unmethylated tumors (HRmultivariable = 2.51, 95%-CI: 1.42-4.43). Despite a significant prognostic effect of RET methylation in stage III patients of a second series, analyzed by MSP, the prognostic effect in stage II patients (n = 231) was not statistically significant (HRmultivariable = 1.16, 95%-CI 0.71-1.92). The third series (n = 294), analyzed by pyrosequencing, confirmed a statistically significant association between RET methylation and poor overall survival in stage II patients (HRmultivariable = 1.91, 95%-CI: 1.04-3.53). Our results show that RET promoter CpG island methylation, analyzed by two different techniques, is associated with a poor prognosis in stage II CRC in two independent series and a poor prognosis in stage III CRC in one series. RET methylation may serve as a useful and robust tool for clinical practice to identify high-risk stage II CRC patients with a poor prognosis. This merits further investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Muriel X.G. Draht, Kim M. Smits, Benjamin Tournier, Valerie Jooste, Caroline Chapusot, Beatriz Carvalho, Arjen H.G. Cleven, Sarah Derks, Kim A.D. Wouters, Eric J.T. Belt, Hein B.A.C. Stockmann, Herman Bril, Matty P. Weijenberg, Piet A. van den Brandt,